LAS VEGAS--(BUSINESS WIRE)--March 9, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it is starting a second Phase II monotherapy trial, of its lead oral entry inhibitor anti-viral agent SP01A, in treatment experienced HIV-infected patients.
